Accurate reporting of minor cannabinoids like CBG and CBGA matters in ways that go beyond a single number. These compounds may influence how THC feels or how long effects last, and they can be important for medical users seeking particular outcomes. If labs and producers do not measure and report these chemicals reliably, anyone trying to use cannabis for symptom relief faces added uncertainty.
This research points toward clearer testing standards and better oversight as ways to build trust in a fast-growing market. For people interested in human potential, growth, and inclusion, reliable information is a basic ingredient for making wise choices and ensuring safe access. Follow the link to see how these findings could shape rules, testing practices, and the everyday experience of consumers exploring cannabis.
Colorado researchers discovered that nearly half of tested cannabis flower products exaggerated their THC levels, while concentrates were mostly accurate. The team’s statewide audit revealed potency inconsistencies that could mislead consumers and affect safe dosing. Beyond THC, the study also found that cannabinoids like CBG and CBGA are underreported. The findings may help shape future regulations and improve consumer trust in the growing cannabis market.